CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma

BACKGROUND: Combination herpes simplex virus (HSV) oncolytic virotherapy and BRAF inhibitors (BRAFi) represent promising immunogenic treatments for BRAF mutant melanoma, but an improved understanding of the immunobiology of combinations is needed to improve on the benefit of immune checkpoint inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bozhanova, Galabina, Hassan, Jehanne, Appleton, Lizzie, Jennings, Victoria, Foo, Shane, McLaughlin, Martin, Chan Wah Hak, Charleen ML, Patin, Emmanuel C, Crespo-Rodriguez, Eva, Baker, Gabby, Armstrong, Edward, Chiu, Matthew, Pandha, Hardev, Samson, Adel, Roulstone, Victoria, Kyula, Joan, Vile, Richard, Errington-Mais, Fiona, Pedersen, Malin, Harrington, Kevin, Ono, Masahiro, Melcher, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961178/
https://www.ncbi.nlm.nih.gov/pubmed/35338089
http://dx.doi.org/10.1136/jitc-2021-004410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961178/
https://www.ncbi.nlm.nih.gov/pubmed/35338089
http://dx.doi.org/10.1136/jitc-2021-004410

Ejemplares similares